Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall.

摘要

Gilenya—approved to reduce relapses and delay disability progression—is competing with Tysabri (natalizumab), which Cambridge, Massachusetts firm Biogen Idec co-markets with Dublin-based Elan, as well as several formulations of interferon (IFN)-β1a, for a share of the $11 billion, and growing, MS market. There are 400,000 people in the US with MS and over 2 million worldwide. The US go-ahead follows the drug's approval in Russia earlier in the month; it is still under consideration by European regulators.